The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Liver and obesity: a narrative review”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2025 |
Amedeo Lonardo, Ralf Weiskirchen. Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?, Exploration of Drug Science. 2025; 3: 1008128. https://doi.org/10.37349/eds.2025.1008128 |
|
2 |
2026 |
Ralf Weiskirchen, Amedeo Lonardo. Treating obesity with GLP-1 RAs: does sex matter? A commentary on the meta-analysis by Yang et al. (J Diabetes 2025;17(3):e70063), Exploration of Endocrine and Metabolic Diseases. 2026; 3: 101458. https://doi.org/10.37349/eemd.2026.101458 |
|
3 |
2025 |
Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz. Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide, Current Medical Research and Opinion. 2025; 41: 2089. https://doi.org/10.1080/03007995.2025.2596430 |
|
4 |
2026 |
Mehdi Karimi, Seyed Morteza Ali Pourfaraji, Peyvand Parhizkar Roudsari, Samira Pirzad. Efficacy of Orlistat on Cardiometabolic Indices in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-analysis of RCTs, Current Therapeutic Research. 2026; 100822100822. https://doi.org/10.1016/j.curtheres.2026.100822 |
|
5 |
2025 |
Amedeo Lonardo, Ralf Weiskirchen. PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD, Exploration of Digestive Diseases. 2025; 4: 100590. https://doi.org/10.37349/edd.2025.100590 |
|
6 |
2025 |
Ralf Weiskirchen, Amedeo Lonardo. Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders, Medical Sciences. 2025; 13: 265. https://doi.org/10.3390/medsci13040265 |
|
7 |
2026 |
Hans-Theo Schon, Ralf Weiskirchen. Silent inflammation: a hidden cause of liver fibrosis, Frontiers in Pharmacology. 2026; 17: 1676534. https://doi.org/10.3389/fphar.2026.1676534 |
|
8 |
2025 |
Amedeo Lonardo, Ralf Weiskirchen. Drug treatment of MASH from none to (too) many options?, Exploration of Medicine. 2025; 6: 1001378. https://doi.org/10.37349/emed.2025.1001378 |
|
9 |
2026 |
Tianhao Wu, Mingyi Du, Tiejun Zhang, Xingdong Chen, Zhenqiu Liu. Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Annals of Hepatology. 2026; 31: 102139102139. https://doi.org/10.1016/j.aohep.2025.102139 |
|
10 |
2025 |
Amedeo Lonardo, Ralf Weiskirchen. Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer, Biomolecules. 2025; 15: 1745. https://doi.org/10.3390/biom15121745 |
|
11 |
2026 |
Mohamad Jamalinia, Ralf Weiskirchen, Amedeo Lonardo. Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications, Medical Sciences. 2026; 14: 44. https://doi.org/10.3390/medsci14010044 |